CN118613277A - 多肽调节物 - Google Patents

多肽调节物 Download PDF

Info

Publication number
CN118613277A
CN118613277A CN202280090526.6A CN202280090526A CN118613277A CN 118613277 A CN118613277 A CN 118613277A CN 202280090526 A CN202280090526 A CN 202280090526A CN 118613277 A CN118613277 A CN 118613277A
Authority
CN
China
Prior art keywords
disease
syndrome
polypeptide
autoimmune
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280090526.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·克雷夫
M·姆科特奇扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Munet Co
Original Assignee
George Munet Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Munet Co filed Critical George Munet Co
Publication of CN118613277A publication Critical patent/CN118613277A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202280090526.6A 2021-12-10 2022-12-08 多肽调节物 Pending CN118613277A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288330P 2021-12-10 2021-12-10
US63/288,330 2021-12-10
PCT/US2022/081186 WO2023108073A2 (en) 2021-12-10 2022-12-08 Polypeptide modulators

Publications (1)

Publication Number Publication Date
CN118613277A true CN118613277A (zh) 2024-09-06

Family

ID=86731448

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280090526.6A Pending CN118613277A (zh) 2021-12-10 2022-12-08 多肽调节物

Country Status (10)

Country Link
US (1) US20250051419A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444339A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546654A (cg-RX-API-DMAC7.html)
KR (1) KR20240118832A (cg-RX-API-DMAC7.html)
CN (1) CN118613277A (cg-RX-API-DMAC7.html)
AU (1) AU2022405109A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241913A1 (cg-RX-API-DMAC7.html)
IL (1) IL313360A (cg-RX-API-DMAC7.html)
MX (1) MX2024006897A (cg-RX-API-DMAC7.html)
WO (1) WO2023108073A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026519808A (ja) * 2023-06-06 2026-06-18 ジョージアミューン・インコーポレイテッド 新規pd-l2変異体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000692A2 (en) * 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN106794235A (zh) * 2014-07-18 2017-05-31 阿德瓦希斯公司 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
US11219694B2 (en) * 2015-09-24 2022-01-11 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
JP2020511144A (ja) * 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
WO2019060888A1 (en) * 2017-09-25 2019-03-28 New York University HETÉRODIMÈRE-FC FUSION PROTEINS
US20210213063A1 (en) * 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3908600A1 (en) * 2019-01-11 2021-11-17 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Fusion protein with immunosuppressive activity

Also Published As

Publication number Publication date
JP2024546654A (ja) 2024-12-26
WO2023108073A3 (en) 2023-10-19
EP4444339A2 (en) 2024-10-16
KR20240118832A (ko) 2024-08-05
CA3241913A1 (en) 2023-06-15
MX2024006897A (es) 2024-06-20
AU2022405109A1 (en) 2024-06-27
US20250051419A1 (en) 2025-02-13
WO2023108073A2 (en) 2023-06-15
IL313360A (en) 2024-08-01
EP4444339A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
JP2026016505A (ja) Il-10バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
CN120424233A (zh) 基于细胞因子的可生物活化药物及其使用方法
JP7863349B2 (ja) ガンマデルタt細胞を刺激するための方法及び組成物
EP3583113B1 (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
US12435121B2 (en) Compositions and methods for stimulating natural killer cells
TW202309073A (zh) IL2R βγc結合化合物及其用途
WO2016115218A1 (en) Antibody drug conjugates for the treatment of immune conditions
KR102669985B1 (ko) Btla 융합 단백질 작용제 및 이의 용도
CN115724986B (zh) 三特异性抗体及其用途
US20250051419A1 (en) Polypeptide modulators
HK40114371A (en) Polypeptide modulators
KR20260021697A (ko) 신규한 pd-l2 돌연변이체
CN116036243A (zh) 受体偏向的peg化il-2变体组合及其应用
HK40081595A (zh) 三特异性抗体及其用途
WO2026096808A1 (en) Trpv6 binding peptide-drug conjugates
WO2025133213A1 (en) Death receptor 5 (dr5)-armored car-t therapeutic
CN114099424A (zh) 一种重组免疫细胞因子的制剂
HK40021169B (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
HK40021169A (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
KR20260003840A (ko) Il-2 접합체에 의한 신규한 암 치료

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40114371

Country of ref document: HK